Is Anti-Acne illuMask Legit? ERSP Finds That Company’s Claims Are
This article was originally published in The Rose Sheet
There has been much buzz about the rise of beauty devices in recent years, but also skepticism about the products’ effectiveness and the legitimacy of associated claims. In its latest review of a home-use acne-treatment device – La Lumiere’s illuMask – the Electronic Retailing Self-Regulatory Program finds the firm’s performance claims adequately substantiated, consistent with previous device decisions.
You may also be interested in...
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.
Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.
House Energy & Commerce Committee Chairman Frank Pallone underscores FDA’s lack of resources and insufficient “regulatory tools” in a memo to Health Subcommittee members going into a 4 December hearing on cosmetics safety issues. The committee’s last hearing on the subject was in 2012 when Pallone unveiled the first version of his Cosmetics Safety Enhancement Act.